- Home
- MODD vs CGTX Comparison
MODD vs CGTX Comparison
Compare MODD & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- CGTX
- Stock Information
- Founded
- MODD 1998
- CGTX 2007
- Country
- MODD United States
- CGTX United States
- Employees
- MODD N/A
- CGTX N/A
- Industry
- MODD Industrial Specialties
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- MODD Health Care
- CGTX Health Care
- Exchange
- MODD Nasdaq
- CGTX Nasdaq
- Market Cap
- MODD 46.3M
- CGTX 53.4M
- IPO Year
- MODD N/A
- CGTX 2021
- Fundamental
- Price
- MODD $0.70
- CGTX $1.67
- Analyst Decision
- MODD
- CGTX Strong Buy
- Analyst Count
- MODD 0
- CGTX 3
- Target Price
- MODD N/A
- CGTX $2.83
- AVG Volume (30 Days)
- MODD 70.8K
- CGTX 8.4M
- Earning Date
- MODD 08-14-2025
- CGTX 08-07-2025
- Dividend Yield
- MODD N/A
- CGTX N/A
- EPS Growth
- MODD N/A
- CGTX N/A
- EPS
- MODD N/A
- CGTX N/A
- Revenue
- MODD N/A
- CGTX N/A
- Revenue This Year
- MODD N/A
- CGTX N/A
- Revenue Next Year
- MODD N/A
- CGTX N/A
- P/E Ratio
- MODD N/A
- CGTX N/A
- Revenue Growth
- MODD N/A
- CGTX N/A
- 52 Week Low
- MODD $0.63
- CGTX $0.22
- 52 Week High
- MODD $2.65
- CGTX $1.97
- Technical
- Relative Strength Index (RSI)
- MODD 43.81
- CGTX 78.08
- Support Level
- MODD $0.69
- CGTX $1.40
- Resistance Level
- MODD $0.75
- CGTX $1.97
- Average True Range (ATR)
- MODD 0.04
- CGTX 0.21
- MACD
- MODD 0.00
- CGTX 0.09
- Stochastic Oscillator
- MODD 16.48
- CGTX 78.78
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.